Loading...

NewAmsterdam Pharma Company N.V.

NAMSWNASDAQ
Healthcare
Biotechnology
$12.20
$-0.36(-2.87%)

NewAmsterdam Pharma Company N.V. (NAMSW) Company Profile & Overview

Explore NewAmsterdam Pharma Company N.V.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

NewAmsterdam Pharma Company N.V. (NAMSW) Company Profile & Overview

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

SectorHealthcare
IndustryBiotechnology
CEOMichael Harvey Davidson FACC, Facp.,

Contact Information

31 35 206 2971
Gooimeer 2-35, Naarden, 1411 DC

Company Facts

68 Employees
IPO DateFeb 10, 2021
CountryNL
Actively Trading

Frequently Asked Questions

;